Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Actinium Pharmaceuticals Inc (ATNM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,579
  • Shares Outstanding, K 115,703
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,600 K
  • 60-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.65
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.11
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/15/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.54 +9.26%
on 03/11/19
0.71 -16.90%
on 02/21/19
+0.05 (+9.26%)
since 02/15/19
3-Month
0.36 +63.43%
on 12/27/18
0.71 -16.90%
on 02/21/19
+0.19 (+47.50%)
since 12/18/18
52-Week
0.33 +78.79%
on 04/25/18
0.87 -31.79%
on 09/26/18
+0.23 (+63.89%)
since 03/16/18

Most Recent Stories

More News
Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that the rejuvenation of R&D activity has bolstered its patent portfolio to a total of 111 issued and pending patents in the U.S. and...

ATNM : 0.58 (-4.92%)
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that it will present a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference,...

ATNM : 0.58 (-4.92%)
Many Look Beyond Chemotherapy to Combat the Swelling Incidence of Cancer

In 2018, the World Health Organization estimated that the global incidence of cancer rose to 18.1 million new cases and 9.6 million deaths. The statistics show that at least 1 in 5 men and 1 in 6 women...

ADXS : 0.39 (-9.30%)
AVEO : 0.59 (unch)
OMED : 0.97 (-2.02%)
SNETD : 0.3900 (+14.71%)
SNET : 0.0106 (-43.92%)
ATNM : 0.58 (-4.92%)
Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that new data from the ongoing pivotal Phase 3 SIERRA trial for Iomab-B was reported in a late breaking oral presentation at the 2019...

ATNM : 0.58 (-4.92%)
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced today that it reported data from its Iomab-ACT program in a poster presentation at the 2019 Transplantation & Cellular Therapy Meetings(TM)...

ATNM : 0.58 (-4.92%)
Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caesars Entertainment Corporation...

GOL : 14.55 (+0.97%)
LAND : 12.36 (+2.66%)
CZR : 8.26 (+2.23%)
ATNM : 0.58 (-4.92%)
ZG : 37.18 (+0.41%)
KFRC : 35.88 (+0.73%)
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that a presentation of data from the pivotal Phase 3 SIERRA trial of Iomab-B has been selected as one of four late breaking oral presentations...

ATNM : 0.58 (-4.92%)
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM), announced that it has further expanded the intellectual property portfolio for the technology underpinning its Iomab-ACT program. The Iomab-ACT program...

ATNM : 0.58 (-4.92%)
Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company") announced today that its novel Phase 1/2 combination trial of Actimab-A and venetoclax has been initiated. Gary Schiller,...

ATNM : 0.58 (-4.92%)
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") announced today that the Medical College of Wisconsin (MCW) has started dosing patients in the second cohort of its novel...

ATNM : 0.58 (-4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade ATNM with:

Business Summary

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition...

See More

Key Turning Points

2nd Resistance Point 0.65
1st Resistance Point 0.63
Last Price 0.58
1st Support Level 0.58
2nd Support Level 0.55

See More

52-Week High 0.87
Fibonacci 61.8% 0.66
Fibonacci 50% 0.60
Last Price 0.58
Fibonacci 38.2% 0.53
52-Week Low 0.33

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar